| Employment |
| Company: Zygosity Limited |
| Recipient: You |
|
| Leadership |
| Company: Zygosity Limited |
| Recipient: You |
|
| Stock and Other Ownership Interests |
| Company: Zygosity Limited |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| No Relationships to Disclose |
|
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Genentech/Roche |
| Recipient: Your Institution |
| Company: Novartis |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Bayer |
| Recipient: Your Institution |
| Company: Janssen |
| Recipient: Your Institution |
| Company: Boehringer Ingelheim |
| Recipient: Your Institution |
| Company: Bristol Myers Squibb |
| Recipient: Your Institution |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: December 2020: PCT/GB2020/053295 (Dec 2019; GB1918692.3) Treatment and prognosis of pancreatic cancer
March 2021: PCT/GB2021/050650 (March 2020; GB2003814.7) Optimising methods for cleavage of target sequences
December 2021: 63/287,720
Gene editing compositions and methods thereof
December 2021: 63/287,724
Gene editing compositions and methods thereof |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|